Clinical trial

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

NCT07517198

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-04-13

PhasePHASE1

Study timeline

Study start (actual)2026-04-13Date precision: day

Registry last updated2026-06-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Solid Tumorunresolved

Small Cell Lung Cancer (SCLC)unresolved

High Grade Neuroendocrine Cancerunresolved

Small Cell Carcinomas of Non-lung Originunresolved

Non-small Cell Lung Cancer (NSCLC)unresolved

Prostate Cancerunresolved

Ovarian Cancerunresolved

Renal Carcinoma (Clear and Non-clear Cell)unresolved

Head and Neck Squamous Cell Carcinoma (HNSCC)unresolved

Hepatic Cancerunresolved

Gastric Cancerunresolved

Triple-negative Breast Cancer (TNBC)unresolved

Interventions

Sponsors & collaborators

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.lead sponsor

Mapped research locations

Los AngelesCalifornia, United States1 Fort WorthTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07517198 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.